Core Viewpoint - Vivani Medical, Inc. is preparing to present its innovative drug implant technology at the 2025 BIO International Convention, highlighting its potential to improve medication adherence and patient outcomes in chronic disease management [1][4]. Company Overview - Vivani Medical, Inc. is a clinical-stage biopharmaceutical company focused on developing miniature, ultra long-acting drug implants using its proprietary NanoPortal™ technology [3]. - The company's lead program, NPM-115, is a six-month GLP-1 (exenatide) implant aimed at chronic weight management for obese or overweight individuals [1][3]. - Vivani's emerging pipeline includes NPM-139 (semaglutide implant) and NPM-119, both designed for chronic weight management and type 2 diabetes treatment, respectively [3]. Industry Context - Medication non-adherence affects approximately 50% of patients, contributing to over $500 billion in annual avoidable healthcare costs and 125,000 preventable deaths in the U.S. [4]. - The current GLP-1 landscape features over 50 new molecular entities in clinical development, with Vivani's differentiated portfolio of miniature implants positioned as a promising therapeutic option [4].